{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:30:30Z","timestamp":1768494630181,"version":"3.49.0"},"posted":{"date-parts":[[2021,7,21]]},"group-title":"Pharmacology and Toxicology","reference-count":55,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase and the exonuclease could overcome this deficiency. Here we report the identification of hepatitis C virus NS5A inhibitors Pibrentasvir and Ombitasvir as SARS-CoV-2 exonuclease inhibitors. In the presence of Pibrentasvir, RNAs terminated with the active forms of the prodrugs Sofosbuvir, Remdesivir, Favipiravir, Molnupiravir and AT-527 were largely protected from excision by the exonuclease, while in the absence of Pibrentasvir, there was rapid excision. Due to its unique structure, Tenofovir-terminated RNA was highly resistant to exonuclease excision even in the absence of Pibrentasvir. Viral cell culture studies also demonstrate significant synergy using this combination strategy. This study supports the use of combination drugs that inhibit both the SARS-CoV-2 polymerase and exonuclease for effective COVID-19 treatment.<\/jats:p>","DOI":"10.1101\/2021.07.21.453274","type":"posted-content","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T23:25:11Z","timestamp":1626909911000},"source":"Crossref","is-referenced-by-count":3,"title":["Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics"],"prefix":"10.64898","author":[{"given":"Xuanting","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3952-7099","authenticated-orcid":false,"given":"Carolina Q.","family":"Sacramento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Jockusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ot\u00e1vio Augusto","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanjuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Fintelman-Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minchen","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jairo R.","family":"Temerozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinshaw J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aitor","family":"Garzia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Tuschl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia T.","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Moreno L.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyue","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021072307550622000_2021.07.21.453274v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"2021072307550622000_2021.07.21.453274v1.2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","year":"2021","journal-title":"Nat. Rev. Microbiol"},{"key":"2021072307550622000_2021.07.21.453274v1.3","doi-asserted-by":"crossref","unstructured":"Shannon, A. et al. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antivir. Res. 178, 104793 (2020).","DOI":"10.1016\/j.antiviral.2020.104793"},{"key":"2021072307550622000_2021.07.21.453274v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10280-3"},{"key":"2021072307550622000_2021.07.21.453274v1.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7498"},{"key":"2021072307550622000_2021.07.21.453274v1.6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","year":"2020","journal-title":"Nature"},{"key":"2021072307550622000_2021.07.21.453274v1.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1201130109"},{"key":"2021072307550622000_2021.07.21.453274v1.8","doi-asserted-by":"crossref","unstructured":"Ju, J. et al. Nucleotide analogues as inhibitors of viral polymerases. bioRXiv (2020). https:\/\/doi.org\/10.1101\/2020.01.30.927574","DOI":"10.1101\/2020.01.30.927574"},{"key":"2021072307550622000_2021.07.21.453274v1.9","doi-asserted-by":"crossref","unstructured":"Ju, J. et al. Nucleotide analogues as inhibitors of SARS-CoV polymerase. Pharmacol. Res. Perspect. 8, e00674 (2020).","DOI":"10.1002\/prp2.674"},{"key":"2021072307550622000_2021.07.21.453274v1.10","doi-asserted-by":"crossref","unstructured":"Jockusch, S. et al. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res. 180, 104857 (2020).","DOI":"10.1016\/j.antiviral.2020.104857"},{"key":"2021072307550622000_2021.07.21.453274v1.11","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","year":"2020","journal-title":"J. Proteome Res"},{"key":"2021072307550622000_2021.07.21.453274v1.12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa334"},{"key":"2021072307550622000_2021.07.21.453274v1.13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/13543776.2021.1880568","article-title":"SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19","volume":"31","year":"2021","journal-title":"Expert Opin. Ther. Pat"},{"key":"2021072307550622000_2021.07.21.453274v1.14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679"},{"key":"2021072307550622000_2021.07.21.453274v1.15","first-page":"1548","article-title":"Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. Molec","volume":"81","year":"2021","journal-title":"Cell"},{"key":"2021072307550622000_2021.07.21.453274v1.16","doi-asserted-by":"crossref","unstructured":"Jockusch, S. et al. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci. Rep. 10, 16577 (2020).","DOI":"10.1038\/s41598-020-73641-9"},{"key":"2021072307550622000_2021.07.21.453274v1.17","doi-asserted-by":"crossref","unstructured":"Khater, S. , Dasgupta, N. & Das, G . Combining SARS-CoV-2 proofreading exonuclease and RNA-dependent RNA polymerase inhibitors as a strategy to combat COVID-19: a high-throughput in silico screen. OSF Preprints. (2020). https:\/\/osf.io\/7X5ek\/","DOI":"10.31219\/osf.io\/7x5ek"},{"key":"2021072307550622000_2021.07.21.453274v1.18","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015610342"},{"key":"2021072307550622000_2021.07.21.453274v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2286-9"},{"key":"2021072307550622000_2021.07.21.453274v1.20","doi-asserted-by":"crossref","unstructured":"Sacramento, C. et al. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J. Antimicrob. Chemother. (2021). https:\/\/doi.org\/10.1093\/jac\/dkab072","DOI":"10.1093\/jac\/dkab072"},{"key":"2021072307550622000_2021.07.21.453274v1.21","unstructured":"Sanders, R. Can hepatitis C drugs help remdesivir fight COVID-19? https:\/\/news.berkeley.edu\/2021\/02\/03\/can-hepatitis-c-drugs-help-remdesiver-fight-covid-19\/"},{"key":"2021072307550622000_2021.07.21.453274v1.22","doi-asserted-by":"crossref","unstructured":"Nguyenla, X. et al. Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. bioRxiv (2020). https:\/\/doi.org\/10.1101\/2020.09.18.302398","DOI":"10.1101\/2020.09.18.302398"},{"key":"2021072307550622000_2021.07.21.453274v1.23","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","year":"2020","journal-title":"Nature Comm"},{"key":"2021072307550622000_2021.07.21.453274v1.24","doi-asserted-by":"crossref","unstructured":"Sheahan, T. R. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883. (2020).","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"2021072307550622000_2021.07.21.453274v1.25","first-page":"e02479","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","year":"2021","journal-title":"Antimicrob. Agents Chemother"},{"key":"2021072307550622000_2021.07.21.453274v1.26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cid\/ciaa410","article-title":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19","volume":"71","year":"2020","journal-title":"Clin. Infect. Dis"},{"key":"2021072307550622000_2021.07.21.453274v1.27","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","article-title":"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study","volume":"1","year":"2020","journal-title":"Lancet Microbe"},{"key":"2021072307550622000_2021.07.21.453274v1.28","unstructured":"https:\/\/www.cdc.gov.tw\/File\/Get\/ht8jUiB_MI-aKnlwstwzvw"},{"key":"2021072307550622000_2021.07.21.453274v1.29","unstructured":"Ju, J. et al. Therapeutics for COVID-19. PCT patent application. Date of filing: Jan. 29, 2021."},{"key":"2021072307550622000_2021.07.21.453274v1.30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijbiomac.2020.12.038","article-title":"Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs","volume":"168","year":"2021","journal-title":"Int. J. Biol. Macromol"},{"key":"2021072307550622000_2021.07.21.453274v1.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"2021072307550622000_2021.07.21.453274v1.32","unstructured":"Essam, A. Comparison of remdesivir versus lopinavir\/ritonavir and remdesivir combination in COVID-19 patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04738045"},{"key":"2021072307550622000_2021.07.21.453274v1.33","first-page":"e10196","article-title":"IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with digital drug development","volume":"6","year":"2020","journal-title":"Bioeng. Transl. Med"},{"key":"2021072307550622000_2021.07.21.453274v1.34","unstructured":"https:\/\/pdf.hres.ca\/dpd_pm\/00040336.PDF"},{"key":"2021072307550622000_2021.07.21.453274v1.35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cts.12840","article-title":"Safety, tolerability, and pharmacokinetics of Remdesivir, an antiviral for treatment of COVID-19, in healthy subjects","volume":"13","year":"2020","journal-title":"Clin. Translat. Sci"},{"key":"2021072307550622000_2021.07.21.453274v1.36","doi-asserted-by":"crossref","unstructured":"Gribble, J. et al. The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog. 17, e1009226 (2021).","DOI":"10.1371\/journal.ppat.1009226"},{"key":"2021072307550622000_2021.07.21.453274v1.37","doi-asserted-by":"crossref","unstructured":"Baddock, H.T. et al. Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification. bioRxiv (2020) https:\/\/doi.org\/10.1101\/2020.08.13.248211","DOI":"10.1101\/2020.08.13.248211"},{"key":"2021072307550622000_2021.07.21.453274v1.38","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acsptsci.1c00022","article-title":"Synergistic inhibition of SARS-CoV-2 replication using Disulfiram\/Ebselen and Remdesivir","volume":"4","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci"},{"key":"2021072307550622000_2021.07.21.453274v1.39","doi-asserted-by":"crossref","unstructured":"Bafna, K. et al. Hepatitis C virus drugs that inhibit the SARS-CoV-2 papain-like protease synergize with Remdesivir to suppress viral replication in cell culture. Cell Rep. 35, 109133 (2021).","DOI":"10.1016\/j.celrep.2021.109133"},{"key":"2021072307550622000_2021.07.21.453274v1.40","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","year":"2021","journal-title":"Nature Comm"},{"key":"2021072307550622000_2021.07.21.453274v1.41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A new and emerging antiviral option in COVID-19","volume":"76","year":"2020","journal-title":"Med. J. Armed Forces India"},{"key":"2021072307550622000_2021.07.21.453274v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"2021072307550622000_2021.07.21.453274v1.43","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"2021072307550622000_2021.07.21.453274v1.44","doi-asserted-by":"crossref","unstructured":"Naydenova, K. et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc. Natl. Acad. Sci. USA 118, e2021946118 (2021).","DOI":"10.1073\/pnas.2021946118"},{"key":"2021072307550622000_2021.07.21.453274v1.45","doi-asserted-by":"crossref","unstructured":"Peng, Q. et al. Structural basis of SARS-CoV-2 polymerase inhibition by Favipiravir. Innovation N.Y. 2, 100080 (2021).","DOI":"10.1016\/j.xinn.2021.100080"},{"key":"2021072307550622000_2021.07.21.453274v1.46","unstructured":"Efficacy and safety of molnupiravir (MK-4482) in hospitalized adult participants with COVID-19 (MK-4482-001). First post Oct. 5, 2020. Last post May 7, 2021. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04575584"},{"key":"2021072307550622000_2021.07.21.453274v1.47","doi-asserted-by":"crossref","unstructured":"Shannon, A. et al. Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527. bioRxiv. https:\/\/doi.org\/10.1101\/2021.03.23.436564 (2021).","DOI":"10.1101\/2021.03.23.436564"},{"key":"2021072307550622000_2021.07.21.453274v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.026"},{"key":"2021072307550622000_2021.07.21.453274v1.49","unstructured":"https:\/\/pubchem.ncbi.nlm.nih.gov\/ accessed in February 2021."},{"key":"2021072307550622000_2021.07.21.453274v1.50","unstructured":"https:\/\/www.wavefun.com\/ accessed in February 2021."},{"key":"2021072307550622000_2021.07.21.453274v1.51","unstructured":"https:\/\/swissmodel.expasy.org\/ accessed in February 2021."},{"key":"2021072307550622000_2021.07.21.453274v1.52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1508686112"},{"key":"2021072307550622000_2021.07.21.453274v1.53","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/protein\/YP_009725309.1?report=fasta accessed in February 2021."},{"key":"2021072307550622000_2021.07.21.453274v1.54","unstructured":"https:\/\/www.ccdc.cam.ac.uk\/solutions\/csd-discovery\/components\/gold\/ accessed in February 2021."},{"key":"2021072307550622000_2021.07.21.453274v1.55","unstructured":"https:\/\/www.pymol.org\/2\/ accessed in February 2021"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.07.21.453274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:58:52Z","timestamp":1768442332000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.07.21.453274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1101\/2021.07.21.453274","relation":{},"subject":[],"published":{"date-parts":[[2021,7,21]]},"subtype":"preprint"}}